Europe Non-Alcoholic Steatohepatitis (Nash) Biomarker Market Forecast 2021-2028
- Report Description Table of Contents
- FAQs
KEY FINDINGS
The Europe non-alcoholic steatohepatitis (NASH) biomarker market is predicted to grow at a CAGR of 19.55% during the forecast period, 2021-2028. The growing awareness about NAFLD, the increasing R&D activities for developing NASH therapeutics, and the expectant launch of NASH therapeutics, are anticipated to fuel the market growth.
MARKET INSIGHTS
Belgium, Italy, Germany, France, the United Kingdom, Russia, Poland, and Rest of Europe, are analyzed for the Europe non-alcoholic steatohepatitis (NASH) biomarker market growth evaluation. In France, the prevalence of the alcoholic fatty liver disease is high in comparison to non-alcoholic fatty liver disease, which is attributed to the increased consumption levels of alcohol. As per the OECD data, almost 17% of the population are obese. There has been a considerable increase in the prevalence of obesity and overweight in the decade, along with surging diabetes. Moreover, France is ranked fourth with regard to clinical trials conducted for non-alcoholic fatty liver disease. Such factors are estimated to boost market growth. In Italy, the prevalence of NASH is low in comparison to other countries. However, NAFLD cases are on the rise. As per the Dionysos Study, fatty liver and elevated alanine transaminase levels were evident in 70% of the northern Italian population. According to another article, a high mortality rate due to liver diseases is expected due to the growing aging population and disability. With the increasing cases of obesity and diabetes, the cases of NASH are set to increase.
COMPETITIVE INSIGHTS
Some of the eminent companies in the market are Gilead Sciences Inc, Merck & Co, Genfit SA, Madrigal Pharmaceuticals, Novartis AG, etc.
Our report offerings include:
- Explore key findings of the overall market
- Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
- Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
- Market Segmentation cater to a thorough assessment of key segments with their market estimations
- Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
- Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
- Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
- Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
The Europe non-alcoholic steatohepatitis (NASH) biomarker market is predicted to grow at a CAGR of 19.55% during the forecast period, 2021-2028. The growing awareness about NAFLD, the increasing R&D activities for developing NASH therapeutics, and the expectant launch of NASH therapeutics, are anticipated to fuel the market growth.
MARKET INSIGHTS
Belgium, Italy, Germany, France, the United Kingdom, Russia, Poland, and Rest of Europe, are analyzed for the Europe non-alcoholic steatohepatitis (NASH) biomarker market growth evaluation. In France, the prevalence of the alcoholic fatty liver disease is high in comparison to non-alcoholic fatty liver disease, which is attributed to the increased consumption levels of alcohol. As per the OECD data, almost 17% of the population are obese. There has been a considerable increase in the prevalence of obesity and overweight in the decade, along with surging diabetes. Moreover, France is ranked fourth with regard to clinical trials conducted for non-alcoholic fatty liver disease. Such factors are estimated to boost market growth. In Italy, the prevalence of NASH is low in comparison to other countries. However, NAFLD cases are on the rise. As per the Dionysos Study, fatty liver and elevated alanine transaminase levels were evident in 70% of the northern Italian population. According to another article, a high mortality rate due to liver diseases is expected due to the growing aging population and disability. With the increasing cases of obesity and diabetes, the cases of NASH are set to increase.
COMPETITIVE INSIGHTS
Some of the eminent companies in the market are Gilead Sciences Inc, Merck & Co, Genfit SA, Madrigal Pharmaceuticals, Novartis AG, etc.
Our report offerings include:
- Explore key findings of the overall market
- Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
- Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
- Market Segmentation cater to a thorough assessment of key segments with their market estimations
- Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
- Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
- Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
- Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Europe Non-Alcoholic Steatohepatitis (Nash) Biomarker Market Forecast 2021-2028
Published By :Inkwood Research
How to Purchase
Purchase reports from our site in few easy clicks. Please follow the description given below to complete your purchase process.
Step 1:
Select the report title of your interest, and Click on Buy Now button next to the Price option.
Step 2:
You will arrive at the Purchase page, where you will be requested to Signup (New User) or Login (Registered User). Please note that in-keeping with the security check on the website, you must submit your full details to avoid any inconvenience arising from incorrectly entered data or counterfeit information.
Step 3:
After SignUp/Login, you will arrive at our Payment Page on Paypal. You will see your Order Summary as well as an option to Choose a way to pay. Select a Payment option from Pay with a Paypal account OR Pay with a Debit or Credit Card. MarketReportOnline accepts Visa, MasterCard, American Express and Discover through Paypal. Fill up the required details in the option of your choice.
Step 4:
Once you follow the required process in Step 3 as mentioned above, you have successfully completed the purchase process.
Step 5:
Once you have successfully completed the purchase process, you will receive a confirmation email. The report will then be emailed to you directly by the publisher, as per our agreement with the publisher. For Orders that are placed after working hours, the delivery of the reports will be made on the next business day. For orders that are placed during weekends, the delivery of the reports will be made on the next 'working' business day. Please note, if you select purchase by invoice, you will receive your report only once the payment has been received. If you have any queries about how to order, please Contact Us.